Drug Eluting Stent (Euca STS Flex DE), Paclitaxel Eluting stent with biodegradable polymer

Coronary Artery Disease

Bare Metal Stent

stent coated with the biodegradable polymer matrix hemoparin and paclitaxel

Drug Eluting Stent

Centro de Estudios en Cardiologia Intervencionista

Clinica IMA

Sanatorio Otamendi y Miroli

A Trial Comparing a Paclitaxel Eluting Stent With Biodegradable Polymer Versus a Bare Metal Stent

Comparison Among a Paclitaxel Eluting Stent With Biodegradable Polymer Versus an Uncoated Bare Metal Stent. A Prospective, Multicentric and Randomized Study.(EUCATAX Trial)

Alfredo E Rodriguez, MD, PHD, FACC, FSCAI

Centro de estudios en Cardiologia Intervencionista

Eucatech AG

749 patients will be assigned into nab-Paclitaxel group.

749 patients will be assigned into paclitaxel group

Breast Cancer

Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.

nab-Paclitaxel+carboplatin

Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.

Paclitaxel+carboplatin

Shengjing Hospital of China Medical University

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective Randomized Controlled Clinical Trial

Pathologic complete remission refers to no invasive tumor cell remnants in the pathological examination of the primary mammary gland and axillary lymph nodes surgically removed. The PCR indicates the proportion of the patients with pathological complete remission to the total number of patients.

The CD44/CD24 expression in the breast tissues will be detected by immunohistochemistry before treatment and at 9 and 18 weeks of treatment, to determine the proportion of tumor stem cells in the lesion.

PFS refers to the time from random enrollment to disease progression or death for any reason indicated by imaging findings. PFS will be recorded within 5 years of follow-up.

OS refers to the time from enrollment to death

Any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment.

Caigang Liu

Principal Investigator

Shengjing Hospital

Esophageal Squamous Cell Carcinoma

Apatinib

Recurrence

Metastasis

apatinib

Shanghai Chest Hospital

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Prospective,Single-arm,and Exploratory Phase II Clinical Study for the Efficacy of Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Squamous Cell Carcinoma After Radical Resection

Zhigang Li

Director, Head of esophageal surgery

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.

Metastatic Cancer

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.

Non Chemotherapy

Chemotherapy and target therapy

Chinese herb medicine

Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of medicine

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

Clinical Studies by Using Alphacait to Screen Drug Combinations for Advanced Solid Tumor

Progression-free survival (PFS) is defined as the time from assignment in the trial to disease progression or death from any cause.

Defined as the time from assignment to death from any cause.

Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy

Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response or stable disease to therapy

Drug-related adverse reactions must be recorded, mainly in the following：myelosuppression including neutropenia, anemia and thrombocytopenia;Cardiac toxicity; muscle fatigue, pain, imbalance; Oral ulcers: the patient's gums, cheeks, throat and tongue are prone to ulcers;nausea, vomiting, constipation or diarrhea;hair loss;skin discomfort;hormonal fluctuations, sexual dysfunction, infertility; damage of the kidney;anxiety and depression.

Expectations of exploratory markers for this study include the status of exploratory biomarkers associated with immunohistochemistry (IHC) or quantitative reverse transcription polymerase chain reaction (qRT-PCR), a new generation sequencing method (NGS), Nanostring technique and / or other methods to evaluate archived and/or newly acquired tumor tissue, as well as its association with disease status and/or (Including but not limited to somatic mutations and other exploratory markers) according to qRT-PCR and NGS techniques, and to evaluate the relationship between the therapeutic response, the status of the biomarker during exploratory treatment and during treatment, and the evaluation of plasma, serum or whole blood samples (including but not limited to somatic mutations and other exploratory markers) The association of the above markers with disease status and / or therapeutic response.

Through publication after study completion

Haining Health-Coming Biotech Co., Ltd.

Alphacait, LLC

This single center, open-label, single arm, non-randomized study is designed to evaluate safety, progression-free survival(PFS),overall survival (OS), objective response rate (OPR), and disease control rate (DCR) of chemotherapy or target therapy or chinese medicine based on the Alphacait screening system in subjects with advanced malignant tumor.

taxus/antifungic

A Trial Comparing a Paclitaxel Eluting Stent With Biodegradable Polymer Versus a Bare Metal Stent

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

Cea mai completă bază de date cu plante medicinale susținută de știință